

# Tuesday 29th of November

## EGID Conferences

- 09.00** **Registration:**  
Welcome Coffee and Symposium Material Distribution
- 09.30** **Philippe FROGUEL - EGID director**  
Introduction and welcoming
- 09.45** **Teresa CARDOSO - CSIC Biomedical Research**  
Post-translational modifications in liver fibrosis
- 10.25** **Jan BOREN - University of Gothenburg**  
Fatty liver, lipoprotein metabolism and cardiovascular risk
- 11.05** **Jimmy BELL - University of Westminster**  
Hepatic Steatosis
- 11.45** **Poster Session and Lunch**
- 14.30** **Charlotte LING - Lund University**  
Alterations in DNA methylation and type 2 diabetes
- 15.10** **Pierre BEDOSSA - University of Paris 7**  
Histological classification of NAFLD: limits and perspectives
- 15.50** **Coffee Time**
- 16.15** **Sophie LOTERSZTAJN - University of Paris Diderot**  
Immunoregulation of liver fibrosis: novel targets
- 16.55** **Best Paper Award**
- 17.15** **Conclusions and EGID's surprise**

# Wednesday 30th of November

## FREE ACCESS TO IDEA SUMMIT

## BIOFIT CONFERENCES



# What is EGID?

First of all EGID (European Genomic Institute for Diabetes) is an international research institute focused on diabetes (type 1 and 2), obesity and associated risks factors. The institute vocation is to diffuse and valorise the "research products".

EGID is the first diabetes institute in France that has recognized international visibility. It is the only center in the world that presents such a wide scope in its field : fundamental research, university education, permanent education, prevention, prediction, clinical applications, industrial valorization and promotion of public health actions.

EGID is destined to play a major role worldwide in the field of diabetes, obesity and its associated factors. The fundamental mission of the institute will be to develop mayor breakthroughs in the understanding of these diseases, as well as their diagnosis and therapeutic treatments.

EGID institute is attached to University of Lille 2, CNRS, Institut Pasteur de Lille, CHRU of Lille and INSERM. EGID is financially supported by the PIA (programme d'investissement d'avenir) LABEX and FEDER (Regional European fund).

## What does EGID symposium deal with?

The European Genomic Institute for Diabetes (EGID) will host its fourth international symposium from November 29, 30th, 2016, Lille, FRANCE.

« The 4th edition of EGID Symposium is organized in collaboration with BioFIT Event ([www.biofit-event.com](http://www.biofit-event.com)) and IDEA Summit ([www.idea-summit-diabetes.com](http://www.idea-summit-diabetes.com)). » This biennial event brings an international focus to our work by the joining of the IDEA Summit and the EGID symposium.

The committee and speakers are world leaders in their fields and will present the latest scientific advances in diabetes and related disorders.

This symposium provides an opportunity for young researchers to present their work via poster presentation and to win the "Best Poster Award" of up to 1000 euros.

The next EGID International Symposium will be held on 29 and 30 November in Lille Grand Palais.

Make a note now in your calendar!

Registration is free of charge, and is available on our website: <http://www.egid.fr>

## Jan Borén, MD, PhD



Jan Borén is chair of the Department of Molecular and Clinical Medicine, Institute of Medicine at the Sahlgrenska Academy; director of the strategic research center Sahlgrenska Center for Cardiovascular and Metabolic Research (CMR), and consultant physician at the Department of Clinical Chemistry at the Sahlgrenska University Hospital.

Professor Borén's long-term interests are to define the mechanisms that regulate secretion and metabolism of atherogenic lipoproteins and clarify their atherogenicity; to develop strategies to prevent retention of atherogenic lipoproteins and identify novel biomarkers for cardiovascular disease; and to elucidate how cardiac uptake of lipoproteins induces lipotoxicity and insulin resistance. His research program is translational and involves both in vitro and in vivo studies, including pathophysiological studies based on vascular and myocardial cells, biopsies and mouse models, and kinetic studies in carefully phenotyped human volunteers.

## Teresa CARDOSO, PhD



Teresa Cardoso Delgado finished her PhD in 2009 in the University of Coimbra, Portugal. During this period her studies were mainly centred in the use of magnetic resonance spectroscopy to assess liver intermediary carbohydrate and lipid metabolism. After this period, she moved to the University of Pittsburgh Medical Center as a post-doctoral Researcher to address the nutrient-mediated molecular mechanism underlying the regulation of liver metabolism. In 2013, she was awarded the prestigious award from the Spanish Association against Cancer (AECC) to develop an independent research line in the laboratory of Dra. Martínez-Chantar at the CIC bioGUNE, Spain. In here, we are mainly interested in the relevance and impact of post-translational modifications (PTMs) in liver disease. More specifically, we have just recently published a manuscript describing for the first time the role of the PTM of NEDDylation in liver fibrosis

## Jimmy D BELL, PhD



Professor Jimmy D Bell completed his PhD in Biochemistry in 1987 (London). He has worked extensively on the development and application of in vivo techniques for the study of disease development, with especial focus on adipose tissue and liver metabolism. Jimmy joined the MRC Clinical Sciences Centre (Imperial College London) in the mid-1990s, where he was appointed Group Head. He recently moved to the University of Westminster to establish a new Research Centre for Optimal Health (ReCOH). Jimmy has published over 200 peer-reviewed papers and authored over a dozen chapters for scientific books

## Charlotte Ling, PhD



Dr Ling obtained her PhD in Endocrinology at University of Gothenburg, Sweden in 2002. After a postdoc at Lund University, where she studied genetics of type 2 diabetes, she dedicated her research to the study of epigenetic mechanisms contributing to type 2 diabetes. Her research group has been involved in many epigenetic discoveries in type 2 diabetes. The group has identified epigenetic modifications in patients with type 2 diabetes and they have shown that genetic and environmental risk factors alter the epigenetic pattern in human pancreatic islets, skeletal muscle and adipose tissue. Charlotte Ling's research is well funded by both national and international funds e.g. she has been awarded a 5 year excellence grant from the Novo Nordisk foundation, EFSD grants and research career grants from the Swedish Research council.

## Pierre Bedossa, PhD



Pierre Bedossa is professor of pathology at the University of Paris. He is currently chairman of the Department of Pathology, Physiology, Nuclear Medicine and Imaging from The University Hospitals of Paris Nord-Val de Seine, France. His main topics of interest are dynamic of fibrosis, progression and regression, viral hepatitis and NASH. He is the founder of the METAVIR scoring system. He has published more than 350 original articles in peer-reviewed journals.

## Sophie Lotersztajn, Dr



Dr. Sophie Lotersztajn serves as Research Director at the INSERM (INstitut de la Sant Et de la Recherche M dicale) in France. Dr. Lotersztajn serves as Principal Investigator and Head of the group Molecular mechanisms of liver fibrosis at the Hospital Henry Mondor in Creteil, Paris. She serves as Member of Scientific Advisory Board at BiOrion Technologies BV. She is author of many publications in high-ranking journals, all about the molecular regulation of hepatic fibrosis. Dr. Lotersztajn is member of the Scientific Committee of INSERM, member of the Editorial Board of American Journal of Physiology and member of the Editorial Board of Molecular Pharmacology.





## **Dominique PACOT**

*General secretary*

dominique.pacot@univ-lille2.fr

Office: 33 (0) 3 20 97 42 51

Cellular: 33 (0)6 42 92 04 94



## **Laurence CELLIER**

*Administrative manager*

laurence.cellier@univ-lille2.fr

Office : 33 (0)3 20 97 42 51

Cellular : 33 (0)6 17 59 12 29